Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks

A two-drug combination of sofosbuvir and ledipasvir cured 94% of previously untreated patients with genotype 1 hepatitis C infection after eight weeks, without the need for ribavirin,

Published
18 December 2013
By
Keith Alcorn
Gilead to seek okay for combo hepatitis C pill in first quarter

Gilead Sciences Inc, based on favorable new clinical trial data, said it will seek U.S. approval in the first quarter of 2014 for a once-daily tablet containing two new treatments for hepatitis C.

Published
18 December 2013
From
Reuters
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

High Cure Rates Observed with Single Tablet Regimen May Eliminate Interferon and Ribavirin from HCV Therapy for Genotype 1 Patients; U.S. NDA Submission Planned for Q1 2014.

Published
18 December 2013
From
Gilead press release
How patent rules could keep new hepatitis C drug from saving 'millions of lives'

While affordable medicine advocates in India prepare to fight the patenting of a new hepatitis C drug, the US works to strengthen pharmaceutical patents through an international trade deal.

Published
18 December 2013
From
Global Post
An interview with Professor Jean-Michel Pawlotsky on how the treatment of HCV infection will change in the near future

Professor Jean-Michel Pawlotsky, Director of the French National Reference Center for Viral Hepatitis B, C and delta, comments on recent developments in hepatitis C treatment - and the price barriers to access in Europe and in low and middle-income countries.

Published
17 December 2013
From
Hepatitis B & C Public Policy Association
Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills

A new battle is looming over access to antiviral medicines in developing countries - this time for treating hepatitis C - more than a decade after a global showdown over the price of AIDS drugs in Africa.

Published
16 December 2013
From
Reuters
Why Talk Of A Hepatitis C Price War Should Act As A Warning To The Pharma Industry-At-Large

Bloomberg reporter Drew Armstrong may have broken one of the most important pharmaceutical news stories of the year on Tuesday when he revealed that a leading US pharmacy benefits manager (PBM) is to take an aggressive stance towards the pricing of new hepatitis C therapies.

Published
11 December 2013
From
Forbes
Express Scripts Pushes Price Competition for Gilead Drug

The biggest U.S. drug benefits manager plans to start a price war over a new generation of hepatitis C treatments that will cost $1,000 a pill, in a bid to drive down spending on the medicines.

Published
11 December 2013
From
Bloomberg
AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C

In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR(12) ) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR(12) rates of GT1a and GT1b were 96 percent and 97 percent, respectively.

Published
10 December 2013
From
AbbVie press release
Activists Condemn Gilead for Exorbitant Price of Their New Hepatitis C Drug

The Fair Pricing Coalition (FPC) today condemned Gilead Sciences for the price set for its direct acting antiviral (DAA) Sovaldi™ (sofosbuvir) - $84,000 for a 12-week course.

Published
10 December 2013
From
Fair Pricing Coalition / The Body

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close